- Home
- SNSE vs KZIA Comparison
SNSE vs KZIA Comparison
Compare SNSE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- KZIA
- Stock Information
- Founded
- SNSE 2005
- KZIA 1994
- Country
- SNSE United States
- KZIA Australia
- Employees
- SNSE N/A
- KZIA N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- KZIA Health Care
- Exchange
- SNSE Nasdaq
- KZIA Nasdaq
- Market Cap
- SNSE 10.3M
- KZIA 9.6M
- IPO Year
- SNSE 2021
- KZIA 1999
- Fundamental
- Price
- SNSE $8.60
- KZIA $10.58
- Analyst Decision
- SNSE Strong Buy
- KZIA Strong Buy
- Analyst Count
- SNSE 5
- KZIA 3
- Target Price
- SNSE $72.50
- KZIA $16.00
- AVG Volume (30 Days)
- SNSE 39.5K
- KZIA 1.9M
- Earning Date
- SNSE 11-14-2025
- KZIA 12-26-2025
- Dividend Yield
- SNSE N/A
- KZIA N/A
- EPS Growth
- SNSE N/A
- KZIA N/A
- EPS
- SNSE N/A
- KZIA N/A
- Revenue
- SNSE N/A
- KZIA $1,199,108.00
- Revenue This Year
- SNSE N/A
- KZIA N/A
- Revenue Next Year
- SNSE N/A
- KZIA N/A
- P/E Ratio
- SNSE N/A
- KZIA N/A
- Revenue Growth
- SNSE N/A
- KZIA N/A
- 52 Week Low
- SNSE $5.00
- KZIA $2.86
- 52 Week High
- SNSE $18.35
- KZIA $29.00
- Technical
- Relative Strength Index (RSI)
- SNSE 44.73
- KZIA 63.23
- Support Level
- SNSE $8.37
- KZIA $7.09
- Resistance Level
- SNSE $9.42
- KZIA $14.42
- Average True Range (ATR)
- SNSE 1.08
- KZIA 1.32
- MACD
- SNSE -0.02
- KZIA 0.42
- Stochastic Oscillator
- SNSE 33.45
- KZIA 56.41
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.